Abstract
Author(s): Yassine Rahim
Our case study was to compare KI67 in young breast cancer patients (less than 35 years), and in older ones. Thirty-three young patients treated between January 1, 2015 and December 31, 2017 . Biomarker studies were done on a biopsy or a surgical specimen before any chemotherapy. Young patients had a higher median value of KI67 (30% [3–95] versus 10% [0–90] P < 0.0001) a higher rate of SBR3 (44 versus 28% P < 04), of mitotic index 3 (35 versus 13% P < 0.001). ER was less frequently positive (56 versus 87%, P < 0.001) as well as PR (38 versus 68% P < 0.001). HER2 was more frequently amplified in young patients (24 versus 10% P < 0.007). Young patients more frequently had a triple negative breast cancer (TNBC) (31 versus 8% P < 0.001). In TNBC patients, KI67 was higher in younger patients (70% [10–95] versus 38% [2–80] P = 0.06). Among young patients, TNBC had a higher KI67 than non TNBC (70% [10–95 versus 20% [3–60] P < 0.001).
Share this article
